Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 263.55B P/E 35.15 EPS this Y 1.00% Ern Qtrly Grth 472.80%
Income 5.95B Forward P/E 13.52 EPS next Y 7.70% 50D Avg Chg 8.00%
Sales 54.4B PEG 2.35 EPS past 5Y 8.87% 200D Avg Chg -1.00%
Dividend 4.00% Price/Book 19.85 EPS next 5Y 6.14% 52W High Chg -11.00%
Recommedations 2.20 Quick Ratio - Shares Outstanding 1.77B 52W Low Chg 14.00%
Insider Own 0.11% ROA - Shares Float 1.76B Beta 0.56
Inst Own 71.74% ROE - Shares Shorted/Prior 13.54M/14.69M Price 149.38
Gross Margin 69.17% Profit Margin 11.02% Avg. Volume 5,937,400 Target Price 183.53
Oper. Margin 28.02% Earnings Date Jul 25 Volume 5,753,546 Change 0.57%
About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV Chatroom

User Image scottybebs Posted - 4 hours ago

$ABBV fuk was that puke

User Image GPS_OS_21_vs_SOC_5 Posted - 4 hours ago

$SLS Targeted AML therapy is the way of the future. $kura's menin inhibitor Ziftomenib targeting kmt2a, is worth $1.6B . B. - Based on Top Line Phase 2 data published Jan 30th. - - SLS009 100% orr, in end stage dying ASXL1 + AML patients - $abbv $rhhby $bmy would pay $25 per sls share just for 009 Right Now. P2 Data in todays Clinical Environment w Genetic Markers is Like P3 Data was 10 years ago - back then p3's were needed to prove the drugs worked, Now We Know based on the BioMarkers. The Kicker - SLS 009 has had no Dose Limiting Toxicity, not one patient with a serious grade 3 or 4 Side Effect, not 1.

User Image Power2k Posted - 5 hours ago

$VKTX $LLY $MRK $NVO $ABBV

User Image iQuicky Posted - 5 hours ago

$ABBV let’s go. Healthcare sector is welcoming the incoming AI and Bitcoin money.

User Image profit_guru Posted - 6 hours ago

$ABBV - it wants to rally above 170 by Friday…strong support at every dips….way oversold…strong pipeline…near term 175…imo

User Image BasedPinkWojak Posted - 7 hours ago

$ABBV is big baby market still throwing a fit over humira? lol. how many times will this dump over the humira "news" that's over 5 years old.

User Image twll Posted - 10 hours ago

$ABBV https://www.saltwire.com/atlantic-canada/news/world/abbvie-lifts-profit-forecast-after-skyrizi-sales-beat-expectations-100960137/

User Image thres Posted - 10 hours ago

$BCLI $ABBV $AMLX $CLNN This article does not even mention Nurown. Funny because Nurown is the lowest hanging fruit of ALS meds and the highest on the totem pole of ALS treatments of choice. ALS patients want more than approved meds for ALS or going into clinical trials while waiting for Nurown because ALS patients know Nurown works and would be their first choice. Go Nurown!!! Nurown works!!! https://finance.yahoo.com/news/trials-watch-four-als-drugs-160250433.html

User Image Eman562 Posted - 04/30/24

$ABBV were will this be by Friday place ya bets

User Image Dr_Feel_Good Posted - 04/30/24

@Mlitton13 yeah pretty much the same with the addition of $ABBV. I will get a boost off the rise in the dxy vs the cdn dollar as well / since I rather own us denominated over Cdn.

User Image Iceman467 Posted - 04/30/24

$ABBV added

User Image Mulhollandr Posted - 04/30/24

$ABBV $BMY $CLNN $JNJ Who’s buying?🤔

User Image woolybully Posted - 04/30/24

@profit_guru bought first position this morning. I like the dividend. Plus it was in a deep down trend and it's coming out of it $ABBV

User Image profit_guru Posted - 04/30/24

$ABBV - going above 170 by Friday on strong guidance and cash flow..imo

User Image lextrading Posted - 04/30/24

$ABBV Resistance is holding so far.

User Image Power2k Posted - 04/30/24

$VKTX $LLY 's 50-70B market cap gain today upon 1st Qtr ER is a huge WAKE-UP call for all the other Big Pharma. Look at the following chart, most of these big guys are still spending $$ billions in late stage clinical development in the Oncology therapeutic area - which is already very very much over-crowded, while having almost NOTHING in their pipeline for the lucrative Obesity/Diabetes area (which has a market estimated at $100 - 130 Billion by 2030). The only two primarily focusing on Obesity/Diabetes area are LLY and $NVO, and that's why both of them are becoming the Two largest pharma in the world, with LLY likely becoming the first $1 Trillion pharma. Whoever buys Viking out now will instantly add tremendous gains to its market cap, and it's a big WIN-WIN for both shareholders. $ABBV $MRK

User Image KaizenPerf671 Posted - 04/29/24

$ABBV

User Image IN0V8 Posted - 04/29/24

$ABBV Barclays cuts target price to $187 from $195 BMO cuts target price to $180 from $195

User Image Thestocktraderhubzee Posted - 04/29/24

$ABBV Barclays Maintains Overweight on AbbVie, Lowers Price Target to $187

User Image Mindonmoney1 Posted - 04/29/24

$ABBV

User Image ST4Life Posted - 04/29/24

$ABBV No juice left in it

User Image DefenseMania Posted - 04/29/24

$RCUS sensing some good news headed our way 😉 $AZN $GILD $AMGN $ABBV

User Image profit_guru Posted - 04/29/24

$ABBV - will trade above 170 by end of the week…way oversold

User Image DiamondHandsBTW Posted - 04/29/24

$ABBV

User Image fatcoin888 Posted - 04/29/24

@Champi2305 $TEVA has no partnership with $ABBV

User Image windycity4 Posted - 04/29/24

$CNC $MOH $ABBV CNC - $72 MOH - $328 Abbvie - $154

User Image profit_guru Posted - 04/28/24

$ABBV - expect upgrades and price target raises tomorrow on strong quarter and pipeline..near term 175…imo

User Image DiamondHandsBTW Posted - 04/28/24

Superb stock the management is some of the best in class focused on long term results not short term outcomes. Very healthy business

User Image KaizenPerf671 Posted - 04/28/24

$ABBV

User Image KaizenPerf671 Posted - 04/28/24

$ABBV @DrioM The’re seeing the glass half-emty. Beats despite falling Market Share for Hirira. Shows other drugs are picking up the slack and Skivizi and Rinvoq are gaining. Friday was just P&P (Profit (Taking) & Panic)

Analyst Ratings
Barclays Overweight Apr 29, 24
BMO Capital Outperform Apr 29, 24
Barclays Overweight Mar 27, 24
Guggenheim Buy Mar 22, 24
Truist Securities Buy Feb 6, 24
Raymond James Outperform Feb 6, 24
BMO Capital Outperform Feb 5, 24
Raymond James Outperform Feb 5, 24
Barclays Overweight Feb 5, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT.. EVP, CHIEF BUS/STRAT OFFICER Dec 26 Sell 154.72 2,912 450,545 55,903 12/28/23
GONZALEZ RICHARD A CHAIRMAN OF THE BOAR.. CHAIRMAN OF THE BOARD AND CEO Jul 31 Sell 148.87 78,500 11,686,295 565,294 08/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Apr 17 Sell 161.84 7,499 1,213,638 35,330 04/19/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Sell 155 15,003 2,325,465 42,829 03/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Option 93.5 15,003 1,402,780 57,832 03/02/23
Siatis Perry C EVP, GC AND SECRETAR.. EVP, GC AND SECRETARY Feb 28 Sell 153.22 12,135 1,859,325 10,377 03/02/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Sell 151.02 28,541 4,310,262 37,921 02/21/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Option 62.09 14,179 880,374 66,462 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Option 51.42 25,000 1,285,500 258,208 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Sell 149.59 25,000 3,739,750 233,208 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Sell 151.02 15,321 2,313,777 62,679 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Option 105.92 15,321 1,622,800 78,000 02/21/23
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Option 104.59 79,801 8,346,387 231,904 05/25/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Sell 151.16 79,801 12,062,719 152,103 05/25/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Option 54.86 83,960 4,606,046 125,583 05/20/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Sell 155 83,960 13,013,800 41,623 05/20/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Option 78.23 200,000 15,646,000 252,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Sell 154.58 200,000 30,916,000 152,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Sell 151.2 300,000 45,360,000 152,103 05/10/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Option 57.21 300,000 17,163,000 252,103 05/10/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Option 58.88 27,690 1,630,387 88,631 03/25/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Sell 159.2 27,690 4,408,248 60,941 03/25/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Option 79.02 11,682 923,112 37,722 03/11/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Sell 150 18,628 2,794,200 19,094 03/11/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Mar 01 Sell 148.12 25,000 3,703,000 16,623 03/02/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Feb 25 Sell 148.43 15,000 2,226,450 41,623 03/01/22
Michael Robert A. Vice Chairman Vice Chairman Feb 25 Sell 148.32 43,105 6,393,334 37,877 03/01/22
Strom Carrie C SVP & Pres Global Al.. SVP & Pres Global Allerg Aesth Feb 07 Sell 141.17 2,396 338,243 42,499 02/08/22
AUSTIN ROXANNE S Director Director Nov 02 Sell 116.42 71,844 8,364,078 49,284 11/04/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Sell 120 13,080 1,569,600 11,595 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Option 114.36 7,080 809,669 18,675 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Option 86.26 20,195 1,742,021 52,946 02/24/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Sell 105 20,195 2,120,475 32,751 02/24/21
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Option 51.42 51,990 2,673,326 51,990 12/01/20
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Sell 105 51,990 5,458,950 12/01/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Option 24.21 4,800 116,208 118,667 11/12/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Sell 93.61 4,800 449,328 113,867 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Option 56.87 194,154 11,041,538 512,796 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Sell 96.76 231,604 22,410,003 318,642 11/12/20